MGMT启动子甲基化对肺癌患者的预后价值：一项荟萃分析。
Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.
作者信息
Chen Chao, Hua Haiqing, Han Chenglong, Cheng Yuan, Cheng Yin, Wang Zhen, Bao Jutao
机构信息
Department of Respiratory Medicine, Jiangyin Hospital of Traditional Chinese Medicine, Nanjing Traditional Chinese Medcine University Jiangyin 214400, China.
出版信息
Int J Clin Exp Pathol. 2015 Sep 1;8(9):11560-4. eCollection 2015.
The role of MGMT promoter methylation in lung cancer (LC) remains controversial. To clarify the association of MGMT promoter methylation with survival in LC, we performed a meta-analysis of the literature with meta-analysis. Trials were selected for further analysis if they provided an independent assessment of MGMT promoter methylation in LC and reported the survival data in the context of MGMT promoter methylation status. Subgroup analyses were conducted according to the study characteristic. A total of 9 trials, which comprised 859 patients, were included in the meta-analysis. The combined hazard ratio (HR) of 1.27 [95% CI 0.88-1.82; test for heterogeneity P = 0.027] suggests that MGMT promoter methylation has none impact on patient survival. In Stage I-III or younger populations, a significant association was found for MGMT promoter methylation in the prognosis of LC. In addition, the heterogeneity disappeared when the analysis was restricted to Stage I-III LC. Our analysis indicates that MGMT promoter methylation in stage I-III or younger patients was significantly correlated with wore survival. Further study is needed to determine these specific subgroups of LC patients.
O-6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化在肺癌（LC）中的作用仍存在争议。为了阐明MGMT启动子甲基化与LC患者生存率之间的关联，我们进行了一项荟萃分析。如果试验提供了对LC中MGMT启动子甲基化的独立评估，并报告了MGMT启动子甲基化状态下的生存数据，则选择这些试验进行进一步分析。根据研究特征进行亚组分析。共有9项试验，包括859名患者，纳入了荟萃分析。合并风险比（HR）为1.27 [95%置信区间0.88 - 1.82；异质性检验P = 0.027]，表明MGMT启动子甲基化对患者生存无影响。在I - III期或较年轻人群中，发现MGMT启动子甲基化与LC预后存在显著关联。此外，当分析仅限于I - III期LC时，异质性消失。我们的分析表明，I - III期或较年轻患者中的MGMT启动子甲基化与较差的生存率显著相关。需要进一步研究以确定这些特定的LC患者亚组。
Zotero 插件